{"trials":[{"trialNumber":"Pharm 21CTP.LEUK01","trialType":"Hematology Acute Leukemia","statusDate":"2026-05-14","title":"SWOG CTP: 21CTP.LEUK01: A Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants with Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia","importDate":"2026-05-15"},{"trialNumber":"Pharm CORT125134-557","trialType":"GYN Other","statusDate":"2026-04-06","title":"Corcept CORT125134-557: A Phase 2 Study of Relacorilant in Combination with Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer (BELLA)","importDate":"2026-05-15"},{"trialNumber":"NRG-GI012","trialType":"GI Other","statusDate":"2026-03-26","title":"NRG-GI012: Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer with Macrovascular Invasion (HELIO-RT)","importDate":"2026-05-15"},{"trialNumber":"Alliance A012303","trialType":"Breast Other","statusDate":"2026-03-13","title":"Alliance A012303: ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade","importDate":"2026-05-15"},{"trialNumber":"COG ANBL1531","trialType":"Pediatric","statusDate":"2026-03-13","title":"COG ANBL1531 - A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)","importDate":"2026-05-15"},{"trialNumber":"COG ALTE2321","trialType":"Pediatric","statusDate":"2026-03-09","title":"COG ALTE2321: Walking Juntos: Developing and Testing a Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors","importDate":"2026-05-15"},{"trialNumber":"Pharm MK2870-022/GOG-3103","trialType":"GYN Other","statusDate":"2026-03-05","title":"Merck MK2870-022/GOG-3103: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)","importDate":"2026-05-15"},{"trialNumber":"INST UNM 2502 PRO-WINDOW","trialType":"GYN Other","statusDate":"2026-03-04","title":"INST UNM 2502 PRO-WINDOW: Evaluating Promising Progestins in Endometrial Cancer Through a Rotating Umbrella Surgical Window Trial – the PRO-WINDOW TRIAL for Endometrial Cancer","importDate":"2026-05-15"},{"trialNumber":"EAY191-E5","trialType":"Advanced Solid Tumors","statusDate":"2026-03-04","title":"ECOG-ACRIN EAY191-E5: ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors","importDate":"2026-05-15"},{"trialNumber":"NRG-GY037","trialType":"GYN Other","statusDate":"2026-02-26","title":"NRG-GY037: A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer","importDate":"2026-05-15"},{"trialNumber":"Pharm MK-1022-016","trialType":"Breast Other","statusDate":"2026-02-24","title":"Merck MK-1022-016: An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EA8134","trialType":"GU Other","statusDate":"2026-02-23","title":"ECOG-ACRIN EA8134: International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)","importDate":"2026-05-15"},{"trialNumber":"Pharm KO-MEN-017","trialType":"Hematology Other","statusDate":"2026-02-12","title":"Kura Oncology KO-MEN-017: Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia","importDate":"2026-05-15"},{"trialNumber":"Pharm HCRN BRE20-468","trialType":"Breast Other","statusDate":"2026-02-11","title":"Hoosier Cancer Research Network HCRN BRE20-468: A Phase II Study of Ribociclib And Endocrine Treatment of Physician’s Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (RaPhLRR Study)\r\n\r\n\r\n","importDate":"2026-05-15"},{"trialNumber":"INST UNM 2503","trialType":"GYN Other","statusDate":"2026-02-10","title":"INST UNM 2503: Consultation Outcomes and Patient Experiences with Fertility Preservation among Gynecologic Cancer Patients in New Mexico (COPinG-NM)","importDate":"2026-05-15"},{"trialNumber":"Pharm MK-2400-001","trialType":"GU Prostate Advanced","statusDate":"2026-02-09","title":"Merck MK-2400-001: A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01) (MK-2400-001)\r\n","importDate":"2026-05-15"},{"trialNumber":"SWOG MM1YA-S01","trialType":"Hematology Acute Leukemia","statusDate":"2026-01-30","title":"SWOG MM1YA-S01: A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial","importDate":"2026-05-15"},{"trialNumber":"MM1OA-S03","trialType":"Hematology Acute Leukemia","statusDate":"2026-01-30","title":"SWOG MM1OA-S03: A Randomized Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant Acute Myeloid Leukemia: A MyeloMATCH Substudy","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN MM1OA-EA02","trialType":"Hematology Acute Leukemia","statusDate":"2026-01-30","title":"ECOG-ACRIN MM1OA-EA02: A Randomized Phase II Study of Venetoclax and HMAbased Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial\n","importDate":"2026-05-15"},{"trialNumber":"CCTG MM1YA-CTG01","trialType":"Hematology Acute Leukemia","statusDate":"2026-01-30","title":"CCTG MM1YA-CTG01: A Measurable Residual Disease (MRD) Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial","importDate":"2026-05-15"},{"trialNumber":"Alliance A022101","trialType":"GI Colorectal Advanced","statusDate":"2026-01-13","title":"Alliance A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)","importDate":"2026-05-15"},{"trialNumber":"COG AALL1732","trialType":"Pediatric","statusDate":"2026-01-06","title":"COG AALL1732 - A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EA2192","trialType":"GI Pancreatic Adjuvant","statusDate":"2025-12-19","title":"ECOG-ACRIN EA2192: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EA2234","trialType":"GI Other","statusDate":"2025-12-15","title":"ECOG-ACRIN EA2234: A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II\r\n","importDate":"2026-05-15"},{"trialNumber":"NRG EAY191-N4","trialType":"GYN Endometrial Advanced","statusDate":"2025-12-15","title":"NRG EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial\r\n","importDate":"2026-05-15"},{"trialNumber":"Pharm LNS8801 Single Patient IND","trialType":"Skin Melanoma Adjuvant","statusDate":"2025-12-03","title":"Linnaeus LNS8801 Single Patient IND: Non-Emergency Use of LNS8801 for Single Patient Expanded Access","importDate":"2026-05-15"},{"trialNumber":"Pharm HQP1351CG301","trialType":"Hematology Chronic Leukemia","statusDate":"2025-12-01","title":"Ascentage Pharma HQP1351CG301: A Global Multicenter, Open Label, Randomized, Phase 3 Registrational Study of Olverembatinib (HQP1351) in Patients with Chronic Phase Chronic Myeloid Leukemia (POLARIS-2)","importDate":"2026-05-15"},{"trialNumber":"COG AHOD2131","trialType":"Pediatric","statusDate":"2025-11-21","title":"Children\u0027s Oncology Group AHOD2131: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin\u0027s Lymphoma ","importDate":"2026-05-15"},{"trialNumber":"COG ACNS1833","trialType":"Pediatric","statusDate":"2025-11-21","title":"COG ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)","importDate":"2026-05-15"},{"trialNumber":"Pharm XL092-311","trialType":"GI Other","statusDate":"2025-11-03","title":"Exelixis, Inc. XL092-311: A Phase 2/3, Multicenter, Randomized Open-label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors","importDate":"2026-05-15"},{"trialNumber":"Pharm GOG-3119/MK-2870-033","trialType":"GYN Other","statusDate":"2025-10-30","title":"GOG-3119/Merck MK-2870-033: A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)","importDate":"2026-05-15"},{"trialNumber":"Alliance A212102","trialType":"Breast Prevention","statusDate":"2025-10-30","title":"Alliance A212102: Blinded Reference Set For Multicancer Early Detection Blood Tests","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EA7222","trialType":"Sarcoma Other","statusDate":"2025-10-30","title":"EA7222: A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas","importDate":"2026-05-15"},{"trialNumber":"COG ANBL2131","trialType":"Pediatric","statusDate":"2025-10-29","title":"COG ANBL2131: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma","importDate":"2026-05-15"},{"trialNumber":"NRG-HN010","trialType":"Head and Neck Other","statusDate":"2025-10-08","title":"NRG-HN010: A Phase II Trial of HER2-Targeted Therapies for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers","importDate":"2026-05-15"},{"trialNumber":"NRG-GY025","trialType":"GYN Endometrial Adjuvant","statusDate":"2025-09-19","title":"NRG Oncology NRG-GY025: A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma","importDate":"2026-05-15"},{"trialNumber":"Alliance A032103","trialType":"GU Other","statusDate":"2025-09-19","title":"Alliance A032103: MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer","importDate":"2026-05-15"},{"trialNumber":"CCTG-NE1","trialType":"GI Other","statusDate":"2025-09-19","title":"CCTG-NE1 - NET RETREAT: A Phase II Study of 177 Lutetium-DOTATATE Retreatment vs. Everolimus in Metastatic/Unresectable Midgut NET","importDate":"2026-05-15"},{"trialNumber":"SWOG S2101","trialType":"Solid Tumors Other","statusDate":"2025-09-18","title":"SWOG S2101: Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study","importDate":"2026-05-15"},{"trialNumber":"SWOG S2303","trialType":"GI Other","statusDate":"2025-09-16","title":"SWOG S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS \u003e/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)","importDate":"2026-05-15"},{"trialNumber":"SWOG S2414","trialType":"Lung Other","statusDate":"2025-09-11","title":"SWOG S2414: A Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants with Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in the AdjuvanT Setting (INSIGHT)","importDate":"2026-05-15"},{"trialNumber":"NRG-CC013","trialType":"Head and Neck Other","statusDate":"2025-09-11","title":"NRG-CC013: A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation","importDate":"2026-05-15"},{"trialNumber":"Pharm MK-2870-023","trialType":"Lung Other","statusDate":"2025-09-11","title":"Merck MK-2870-023: Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer","importDate":"2026-05-15"},{"trialNumber":"SWOG S1800E","trialType":"Lung Other","statusDate":"2025-09-11","title":"SWOG S1800E: A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)","importDate":"2026-05-15"},{"trialNumber":"SWOG S1931","trialType":"GU RenalCell Adjuvant","statusDate":"2025-09-08","title":"SWOG S1931: Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)","importDate":"2026-05-15"},{"trialNumber":"Pharm LNS-103","trialType":"Skin Melanoma Other","statusDate":"2025-08-27","title":"Linnaeus LNS-103: A Multicenter, Open-Label, Randomized Study to Assess the Antitumor Activity of LNS8801 With and Without Pembrolizumab in Patients With Biomarker Selected Unresectable Treatment-Refractory Melanoma ","importDate":"2026-05-15"},{"trialNumber":"Alliance A032201","trialType":"GU Renal Cell Advanced","statusDate":"2025-08-25","title":"Alliance A032201: Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma - STRIKE","importDate":"2026-05-15"},{"trialNumber":"NRG-LU008","trialType":"Lung NSCLC Advanced","statusDate":"2025-08-15","title":"NRG-LU008: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer","importDate":"2026-05-15"},{"trialNumber":"WF2304-A172401","trialType":"CCDR","statusDate":"2025-08-15","title":"Wake Forest WF2304-A172401: Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics","importDate":"2026-05-15"},{"trialNumber":"INST WASHU 202307204","trialType":"GYN Other","statusDate":"2025-08-11","title":"INST WASHU 202307204: UPLifT-Endo: Uterine Preservation via Lifestyle Transformation: A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation In Premenopausal Women With Obesity and Atypical Endometrial Hyperplasia or Grade 1 Endometrial Cancer\r\n","importDate":"2026-05-15"},{"trialNumber":"COG AREN1921","trialType":"Pediatric","statusDate":"2025-08-01","title":"Children’s Oncology Group AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)","importDate":"2026-05-15"},{"trialNumber":"COG ARST2032","trialType":"Pediatric","statusDate":"2025-08-01","title":"Children’s Oncology Group ARST2032: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low-Risk Fusion Negative Rhabdomyosarcoma","importDate":"2026-05-15"},{"trialNumber":"EA2185","trialType":"GI Other","statusDate":"2025-08-01","title":"EA2185: Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs ","importDate":"2026-05-15"},{"trialNumber":"MM1MDS-A01","trialType":"Hematology Other","statusDate":"2025-07-30","title":"Alliance MM1MDS-A01: A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study","importDate":"2026-05-15"},{"trialNumber":"SWOG S2114","trialType":"Hematology Lymphoma Non-Hodgkins","statusDate":"2025-07-11","title":"SWOG S2114: A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment For Relapsed/Refractory Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma\n","importDate":"2026-05-15"},{"trialNumber":"SWOG S2312","trialType":"GU Prostate Advanced","statusDate":"2025-06-30","title":"SWOG S2312: A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EAQ222CD","trialType":"Solid Tumors Other","statusDate":"2025-06-26","title":"ECOG-ACRIN EAQ222CD: Effectiveness of Out-of-Pocket Cost COMmunication and Financial Navigation (CostCOM) in Cancer Patients","importDate":"2026-05-15"},{"trialNumber":"Pharm 02AB21-TucErBit","trialType":"Breast Other","statusDate":"2025-06-12","title":"Criterium, Inc. 02AB21-TucErBit: A Phase II Study Of The Safety, Tolerability And Antitumor Activity Of Tucatinib In Combination With Eribulin And Trastuzumab In Patients With Pretreated Unresectable Locally Advanced Or Metastatic Her2+ Breast Cancer","importDate":"2026-05-15"},{"trialNumber":"Alliance A012103","trialType":"Breast Other","statusDate":"2025-06-11","title":"Alliance A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy","importDate":"2026-05-15"},{"trialNumber":"Alliance A081801","trialType":"Lung SCLC Adjuvant","statusDate":"2025-06-11","title":"Alliance A081801: Integration Of Immunotherapy Into Adjuvant Therapy For Resected NSCLC: ALCHEMIST Chemo-IO","importDate":"2026-05-15"},{"trialNumber":"NRG-GY036","trialType":"GYN Other","statusDate":"2025-05-20","title":"NRG-GY036: A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy\r\n\r\nGI J. Sanchez, L. Bogart \u0026 B. Barnes ","importDate":"2026-05-15"},{"trialNumber":"Pharm BMS CA071-1000","trialType":"GU Prostate Adjuvant","statusDate":"2025-05-19","title":"BMS CA071-1000: A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus a Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)","importDate":"2026-05-15"},{"trialNumber":"Pharm Janssen 75276617ALE1001","trialType":"Hematology Acute Leukemia","statusDate":"2025-05-08","title":"Janssen 75276617ALE1001: A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants with Acute Leukemia","importDate":"2026-05-15"},{"trialNumber":"COG ALTE2131","trialType":"Pediatric","statusDate":"2025-05-07","title":"COG ALTE2131: Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer","importDate":"2026-05-15"},{"trialNumber":"RTOG 1216","trialType":"Head and Neck Advanced","statusDate":"2025-05-01","title":"RTOG 1216: Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck","importDate":"2026-05-15"},{"trialNumber":"INST CR2502","trialType":"Hematology Acute Leukemia","statusDate":"2025-04-28","title":"INST CR2502: Continuation of tyrosine kinase inhibitors after chemotherapy in pediatric Ph+ ALL: A multi-site retrospective study","importDate":"2026-05-15"},{"trialNumber":"INST Duke Pro00103465","trialType":"GYN Other","statusDate":"2025-04-21","title":"INST Duke Pro00103465: Endometrial Cancer Molecularly Targeted Therapy Consortium","importDate":"2026-05-15"},{"trialNumber":"Alliance CTIU2317-A082304-S2402","trialType":"Lung Other","statusDate":"2025-04-18","title":"Alliance CTIU2317-A082304-S2402: Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer - PROSPECT LUNG","importDate":"2026-05-15"},{"trialNumber":"Pharm Emergency Use of CD34 HUD","trialType":"Hematology Stem Cell Transplant","statusDate":"2025-04-16","title":"Emergency Use of CD34 Selected Stem Cell Humanitarian Use Device (HUD)","importDate":"2026-05-15"},{"trialNumber":"Pharm BMS CA245-0001","trialType":"Lung SCLC Advanced","statusDate":"2025-04-11","title":"BMS CA245-0001: A Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide vs Atezolizumab in Combination with Carboplatin plus Etoposide as First-line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer (TIGOS)","importDate":"2026-05-15"},{"trialNumber":"Pharm Janssen OrigAMI-2 61186372COR3001","trialType":"GI Colorectal Advanced","statusDate":"2025-04-08","title":"Janssen OrigAMI-2 61186372COR3001: A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","importDate":"2026-05-15"},{"trialNumber":"NRG-BN013","trialType":"Brain Other","statusDate":"2025-04-02","title":"NRG-BN013: Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) Versus Fractionated SRS (FSRS) for Intact Brain Metastases","importDate":"2026-05-15"},{"trialNumber":"NRG-CC005","trialType":"GI Other","statusDate":"2025-03-31","title":"NRG Oncology NRG-CC005: FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)","importDate":"2026-05-15"},{"trialNumber":"Pharm Janssen 61186372NSC2012","trialType":"Lung Other","statusDate":"2025-03-28","title":"Janssen 61186372NSC2012: A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (COPERNICUS)","importDate":"2026-05-15"},{"trialNumber":"SWOG S2007","trialType":"Breast Advanced","statusDate":"2025-02-21","title":"SWOG S2007: A Phase II Trial Of Sacituzumab Govitecan (IMMU-132) (NSC #820016) For Patients With HER2-Negative Breast Cancer and Brain Metastases","importDate":"2026-05-15"},{"trialNumber":"INST UNM 2403","trialType":"CCDR","statusDate":"2025-02-21","title":"INST UNM 2403: Assessing Cascade Testing: A Cross-Sectional Study Evaluating Disclosure and Subsequent Familial Testing (ACT Study)","importDate":"2026-05-15"},{"trialNumber":"Pharm ASCO-CDK Pro00075309","trialType":"Breast Advanced","statusDate":"2025-01-08","title":"ASCO CDK Pro00075309: Comparing Oral Drug Dosing Strategies in Older Patients with Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study","importDate":"2026-05-15"},{"trialNumber":"SWOG MYELOMATCH","trialType":"Hematology Other","statusDate":"2024-12-13","title":"SWOG MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials","importDate":"2026-05-15"},{"trialNumber":"NRG-GY026","trialType":"GYN Endometrial Neoadjuvant","statusDate":"2024-12-10","title":"NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-Zzfx (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma","importDate":"2026-05-15"},{"trialNumber":"COG APAL2020SC","trialType":"Pediatric","statusDate":"2024-12-05","title":"COG APAL2020SC: Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias","importDate":"2026-05-15"},{"trialNumber":"INST DFCI 2024-01","trialType":"Pediatric","statusDate":"2024-11-21","title":"INST DFCI 2024-01 Disparities in Clinical Trial Enrollment Among Adolescents and Young Adults with Cancer","importDate":"2026-05-15"},{"trialNumber":"Pharm LYL314-101 (MPCT-012L)","trialType":"Hematology Lymphoma Non-Hodgkins","statusDate":"2024-11-21","title":"LYL314-101: A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of LYL314, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants with Aggressive BCell Non-Hodgkin Lymphoma","importDate":"2026-05-15"},{"trialNumber":"SWOG S1501","trialType":"Breast Advanced","statusDate":"2024-11-01","title":"SWOG S1501: Prospective Observational Cohort Study of Patients with Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity","importDate":"2026-05-15"},{"trialNumber":"NRG-CC012CD","trialType":"CCDR","statusDate":"2024-10-30","title":"NRG-CC012CD: Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment (SYMON)","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EA5182","trialType":"Lung NSCLC Advanced","statusDate":"2024-10-16","title":"ECOG-ACRIN EA5182: Randomized Phase III Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)","importDate":"2026-05-15"},{"trialNumber":"SWOG S1900G","trialType":"Lung Other","statusDate":"2024-10-15","title":"SWOG S1900G: Randomized Phase II Study of USAN (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)","importDate":"2026-05-15"},{"trialNumber":"INST UNM 2304","trialType":"GYN Endometrial Adjuvant","statusDate":"2024-10-01","title":"INST UNM 2304: PRO Endo/ A prospective observational study in patients diagnosed with pre-invasive endometrial intraepithelial neoplasia or early-stage endometrial cancer who choose to have treatment with progestin therapy","importDate":"2026-05-15"},{"trialNumber":"CCTG-CO32","trialType":"GI Colorectal Neoadjuvant","statusDate":"2024-09-27","title":"Canadian Cancer Trials Group CCTG-CO32: The NEO-RT Trial: A Phase 3 Randomized Trial of Neoadjuvant Chemotherapy, Excision and Observation Versus ChemoRadioTherapy for Early Rectal Cancer","importDate":"2026-05-15"},{"trialNumber":"Pharm MCLA-158-CL03 (PET03)","trialType":"Head and Neck Advanced","statusDate":"2024-09-20","title":"Merus MCLA-158-CL03 (PET03): A phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma","importDate":"2026-05-15"},{"trialNumber":"COG AGCT1532","trialType":"Pediatric","statusDate":"2024-09-17","title":"COG AGCT1532 / ANZUP 1302: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours","importDate":"2026-05-15"},{"trialNumber":"Pharm MCLA-158-CL02","trialType":"Head and Neck Advanced","statusDate":"2024-09-11","title":"Merus N.V. MCLA-158-CL02: A Phase III Open-Label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared with Investigator’s Choice Monotherapy Treatment in Previously Treated Patients with Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma","importDate":"2026-05-15"},{"trialNumber":"GOG-3088","trialType":"GYN Other","statusDate":"2024-09-09","title":"GOG-3088: A Randomized Phase II Study of Letrozole Versus Observation in Patients with Newly Diagnosed Uterine Leiomyosarcoma","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EA8134","trialType":"GU Other","statusDate":"2024-09-05","title":"ECOG-ACRIN EA8134: International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)","importDate":"2026-05-15"},{"trialNumber":"Pharm Janssen 68284528MMY4006","trialType":"Hematology Other","statusDate":"2024-08-29","title":"Janssen 68284528MMY4006: Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma","importDate":"2026-05-15"},{"trialNumber":"Pharm J3M-MC-JZQB","trialType":"Lung NSCLC Advanced","statusDate":"2024-08-21","title":"Eli Lilly and Company J3M-MC-JZQB: SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EA8192","trialType":"GU Ureter Adjuvant","statusDate":"2024-07-16","title":"ECOG-ACRIN EA8192: A Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy","importDate":"2026-05-15"},{"trialNumber":"GOG-3068/HOTT GOG Foundation","trialType":"GYN Ovarian Advanced","statusDate":"2024-07-01","title":"GOG Foundation GOG-3068/HOTT: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin Versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients With Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer (Heated Ovarian Treatment Trial)\r\n","importDate":"2026-05-15"},{"trialNumber":"SWOG S1900G","trialType":"Lung Other","statusDate":"2024-05-24","title":"SWOG S1900G: Randomized Phase II Study of USAN (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)","importDate":"2026-05-15"},{"trialNumber":"INST UNM 2308","trialType":"GYN Other","statusDate":"2024-05-18","title":"INST UNM 2308: Improving Equity in Gynecologic Cancer Clinical Trials Through Integration of Social Precarity","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EAQ221CD","trialType":"Breast Other","statusDate":"2024-05-18","title":"ECOG-ACRIN EAQ221CD: Improving Medication Adherence in Metastatic Breast Cancer using a CONnected CUstomized Treatment Platform (CONCURxP)","importDate":"2026-05-15"},{"trialNumber":"NRG-GU013","trialType":"GU Prostate Advanced","statusDate":"2024-05-14","title":"NRG-GU013: The Phase III `High Five Trial\u0027 Five Fraction Radiation For High-Risk Prostate Cancer","importDate":"2026-05-15"},{"trialNumber":"NRG-BR009","trialType":"Breast Adjuvant","statusDate":"2024-05-10","title":"NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)","importDate":"2026-05-15"},{"trialNumber":"Pharm JCAR017-EAP-001","trialType":"Hematology Lymphoma Non-Hodgkins","statusDate":"2024-04-26","title":"Juno JCAR17-EAP-001: Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release ","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EAY191-A6","trialType":"GI Other","statusDate":"2024-03-21","title":"(Study Closed to IRB 05 May 2026) ECOG-ACRIN EAY191-A6: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations: A ComboMATCH Treatment Trial","importDate":"2026-05-15"},{"trialNumber":"Pharm GS-US-595-6184 (AFT-65)","trialType":"Breast Adjuvant","statusDate":"2024-01-31","title":"Gilead Sciences GS-US-595-6184 AFT-65/ASCENT-05: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician\u0027s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy","importDate":"2026-05-15"},{"trialNumber":"Pharm Amgen Inc 20190341","trialType":"Lung NSCLC Advanced","statusDate":"2024-01-10","title":"Amgen Inc, 20190341: A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)","importDate":"2026-05-15"},{"trialNumber":"INST CR2302","trialType":"Hematology Other","statusDate":"2023-12-18","title":"INST CR2302: Morphological and molecular characteristics of acute leukemia/myeloid malignancies and clinical outcome to different treatment strategies","importDate":"2026-05-15"},{"trialNumber":"INST 2108","trialType":"CCDR","statusDate":"2023-12-14","title":"INST 2108: Participant Engagement – Cancer Genome Sequencing (PE-CGS) Research Center: Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing ","importDate":"2026-05-15"},{"trialNumber":"INST UAZ FALCON","trialType":"Lung Other","statusDate":"2023-10-23","title":"University of Arizona INST UAZ FALCON: Ethnicity and Lung Cancer Survival: A Test of the Hispanic Sociocultural Hypothesis ","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EA3161","trialType":"Head and Neck Advanced","statusDate":"2023-10-13","title":"ECOG-ACRIN EA3161: A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC","importDate":"2026-05-15"},{"trialNumber":"SWOG S2205","trialType":"Supportive","statusDate":"2023-09-26","title":"SWOG S2205: ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Included Peripheral Neuropathy","importDate":"2026-05-15"},{"trialNumber":"INST CR2301","trialType":"Hematology Other","statusDate":"2023-08-25","title":"INST CR2301: Retrospective Review of Patients with BPCDN treated from 2000-2023","importDate":"2026-05-15"},{"trialNumber":"Pharm BNT113-01","trialType":"Head and Neck Advanced","statusDate":"2023-08-25","title":"BioNTech BNT113-01: An Open Label Phase II Randomized Trial of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy as a First Line Therapy in Patients With Unresectable Recurrent, or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Which is Positive for Human Papilloma Virus 16 (HPV16+) and Expresses PD-L1 (AHEAD-MERIT)","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EAY191","trialType":"Advanced Solid Tumors","statusDate":"2023-08-21","title":"ECOG-ACRIN EAY191: Molecular Analysis for Combination Therapy Choice (ComboMATCH)\n","importDate":"2026-05-15"},{"trialNumber":"ECOG-ACRIN EA8192","trialType":"GU Ureter Adjuvant","statusDate":"2023-05-22","title":"ECOG-ACRIN EA8192: A Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy","importDate":"2026-05-15"},{"trialNumber":"ALLIANCE A211901","trialType":"Head and Neck Other","statusDate":"2023-03-31","title":"ALLIANCE A211901: Reaching Rural Cancer Survivors Who Smoke Using Text-Based Cessation Interventions","importDate":"2026-05-15"},{"trialNumber":"INST CR1903","trialType":"GI Other","statusDate":"2023-03-18","title":"INST CR1903: Prognostic Factors in Hepato-Pancreato-Biliary Patients of New Mexico","importDate":"2026-05-15"},{"trialNumber":"Pharm 02AB21-TucErBit","trialType":"Breast Other","statusDate":"2023-01-13","title":"Criterium, Inc. 02AB21-TucErBit: A Phase II Study Of The Safety, Tolerability And Antitumor Activity Of Tucatinib In Combination With Eribulin And Trastuzumab In Patients With Pretreated Unresectable Locally Advanced Or Metastatic Her2+ Breast Cancer","importDate":"2026-05-15"},{"trialNumber":"INST CR2204","trialType":"CCDR","statusDate":"2022-12-04","title":"INST CR2204: Retrospective Review of Patients with Ph-like ALL Treated at UNM from 2018-2022","importDate":"2026-05-15"},{"trialNumber":"INST CR2201","trialType":"GI Other","statusDate":"2022-08-29","title":"(STUDY LEVEL ONLY) INST CR2201: Analyzing clinical outcomes and genomic data of New Mexico’s American Indian patient population treated with immune checkpoint inhibitors for various cancers including non-small cell lung cancers, melanoma, head and neck squamous cell carcinoma, renal cell carcinoma, and gastrointestinal cancers \n","importDate":"2026-05-15"},{"trialNumber":"NRG-GI008","trialType":"GI Colorectal Adjuvant","statusDate":"2022-08-18","title":"NRG Oncology NRG-GI008: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease","importDate":"2026-05-15"},{"trialNumber":"INST CR2203","trialType":"CCDR","statusDate":"2022-06-01","title":"(STUDY LEVEL ONLY) INST CR2203: Differences in Race and Ethnicity in Cancer Somatic and Germline Genetic Mutations   ","importDate":"2026-05-15"},{"trialNumber":"INST UNM 2004","trialType":"Breast Adjuvant","statusDate":"2022-05-27","title":"INST UNM 2004: Patient Understanding of the Benefit of Adjuvant Endocrine Therapy in Breast Cancer","importDate":"2026-05-15"},{"trialNumber":"NRG-GU009","trialType":"GU Other","statusDate":"2022-04-15","title":"NRG Oncology NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT)","importDate":"2026-05-15"},{"trialNumber":"SWOG S2104","trialType":"GI Pancreatic Adjuvant","statusDate":"2022-03-21","title":"SWOG S2104: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumor","importDate":"2026-05-15"},{"trialNumber":"ASCO TAPUR","trialType":"Advanced Solid Tumors","statusDate":"2021-10-20","title":"ASCO TAPUR: Targeted Agent and Profiling Utilization Registry (TAPUR™) Study","importDate":"2026-05-15"},{"trialNumber":"INST CR2103","trialType":"GU Other","statusDate":"2021-08-16","title":"INST CR2103: Prognostic Factors in Prostate Cancer Patients of New Mexico ","importDate":"2026-05-15"},{"trialNumber":"INST DARE","trialType":"Breast Advanced","statusDate":"2021-08-09","title":"INST DARE: CRITERIUM Inc., Academic Breast Cancer Consortium DARE: A randomized, phase II trial of circulating tumor DNA-guided second line adjuvant therapy for high residual risk, stage II-III, estrogen receptor positive, HER2 negative breast cancer (DARE)","importDate":"2026-05-15"},{"trialNumber":"INST UNM 2201","trialType":"GYN Other","statusDate":"2021-07-04","title":"INST UNM 2201: Decision-making regarding ovarian cancer risk-reduction among women of color who carry a BRCA mutation","importDate":"2026-05-15"},{"trialNumber":"INST UNM 1903","trialType":"Hematology Other","statusDate":"2021-06-25","title":"INST UNM 1903: Collection of Apheresed Leukocytes for Research and Cell Therapy Process Development\n","importDate":"2026-05-15"},{"trialNumber":"INST CR2101","trialType":"Supportive","statusDate":"2021-06-01","title":"INST CR2101: Retrospective Analysis Of Cardiovascular Risk Factors And Cardiovascular Outcomes In Native American Patients Receiving Cancer Directed Therapies \n\n","importDate":"2026-05-15"},{"trialNumber":"COG AGCT1531","trialType":"Pediatric","statusDate":"2020-12-16","title":"COG AGCT1531: A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors","importDate":"2026-05-15"},{"trialNumber":"CIBMTR Protocol for a Research Database","trialType":"Epidemiological","statusDate":"2020-11-10","title":"CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries","importDate":"2026-05-15"},{"trialNumber":"NRG-CC008","trialType":"GYN Other","statusDate":"2020-09-02","title":"NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing The Noninferiority Of Salpingectomy To Salpingo-Oophorectomy To Reduce The Risk Of Ovarian Cancer Among BRCA1 Carriers [SOROCk]","importDate":"2026-05-15"},{"trialNumber":"UNM 1509","trialType":"GYN Other","statusDate":"2020-06-29","title":"INST UNM 1509: Single Institution (UNM) Prospective Laboratory Study of Cancer and Immune Cells in the Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies\r\n","importDate":"2026-05-15"},{"trialNumber":"SWOG S1703","trialType":"Breast Other","statusDate":"2020-03-02","title":"SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer ","importDate":"2026-05-15"},{"trialNumber":"NNR-18.330T","trialType":"Ill Defined","statusDate":"2019-05-19","title":"Thinking Zinc: A Study of Zinc Supplementation to Ameliorate Adverse Effects of Mine Waste Exposure on the Navajo Nation\n","importDate":"2026-05-15"},{"trialNumber":"SWOG LungMAP","trialType":"Lung NSCLC Advanced","statusDate":"2019-03-14","title":"SWOG LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screen Study)","importDate":"2026-05-15"},{"trialNumber":"CCTG MA.39","trialType":"Breast Neoadjuvant","statusDate":"2018-09-05","title":"CCTG MA.39:  A Randomized Trial Of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer","importDate":"2026-05-15"},{"trialNumber":"INST UNM 1512","trialType":"Hematology Acute Leukemia","statusDate":"2018-05-23","title":"INST UNM 1512: A New Drug Discovery Platform using High Throughput Flow Cytometry and a PDX Tissue Repository in AML and MDS","importDate":"2026-05-15"},{"trialNumber":"INST UNM 1521 - TCCP","trialType":"Epidemiological","statusDate":"2017-12-08","title":"INST UNM 1521: Total Cancer Care Protocol: A Lifetime Partnership with Patients Who Have or May be at Risk of Having Cancer\n","importDate":"2026-05-15"},{"trialNumber":"CIBMTR Protocol for a Research Database","trialType":"Epidemiological","statusDate":"2017-06-29","title":"CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries","importDate":"2026-05-15"},{"trialNumber":"CIBMTR Protocol for a Research Database","trialType":"Epidemiological","statusDate":"2017-06-29","title":"CIBMTR Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries","importDate":"2026-05-15"},{"trialNumber":"DCP-001","trialType":"Supportive","statusDate":"2016-08-17","title":"DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)","importDate":"2026-05-15"},{"trialNumber":"DCP-001A","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-05-15"},{"trialNumber":"DCP-001B","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-05-15"},{"trialNumber":"DCP-001C","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-05-15"},{"trialNumber":"DCP-001D","trialType":"Supportive","statusDate":"2016-08-17","title":"Division of Cancer Prevention DCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)\n****This is for additional enrollments.  Enter the Study Number in the patient status notes.***********","importDate":"2026-05-15"},{"trialNumber":"COG APEC14B1","trialType":"Epidemiological","statusDate":"2016-07-07","title":"COG APEC14B1: The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study\r\n","importDate":"2026-05-15"}]}